S
SenoRx, Inc.
Designs, develops, manufactures and markets minimally invasive devices for the diagnosis and treatment of breast cancer
About SenoRx, Inc.
C. R. Bard, Inc., a subsidiary of BD (Becton, Dickinson and Company), is a multinational developer, manufacturer, and marketer of medical devices. The company operates in various medical fields including vascular, urology, oncology, and surgical specialties. Bard's core business involves creating innovative medical devices that address the challenges faced by healthcare professionals and patients. The company serves a diverse range of clients, primarily healthcare professionals and institutions, providing them with high-quality products designed to improve patient outcomes and streamline healthcare processes.
Bard's business model focuses on the development and commercialization of advanced medical devices. Revenue is generated through the sale of these devices to hospitals, clinics, and other healthcare facilities. The company also invests heavily in research and development to continuously innovate and expand its product portfolio. Bard's commitment to quality and innovation has made it a trusted name in the medical device industry for over a century.
The market Bard operates in is highly competitive and regulated, requiring adherence to stringent quality and safety standards. Despite these challenges, Bard has maintained a strong market presence through its dedication to delivering reliable and effective medical solutions. The company's products are designed to provide the most compassionate patient experience possible, ensuring both healthcare professionals and patients benefit from their use.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1998
- Headquarters
- Irvine, United States
- Employees
- 56
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biopsy, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2010 | $200M | $200M | C. R. Bard | — |
| IPO✓Exit | Mar 2007 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for SenoRx, Inc. is 240 monthly website visits. SenoRx, Inc.'s team declined 8.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
MPM BioImpact
Mayfield
Domain Associates
Other known investors2 additional known investors
- CBC. R. Bard
Escalate Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SenoRx, Inc. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SenoRx, Inc.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







